Blood Screening Market

1
MarketsandMarkets Presents
 Blood Screening Market Size, By Technology,
20142021
http//www.marketsandmarkets.com/Market-Reports/bl
ood-screening-market-267747042.html
2
The report "Blood Screening Market by Technology
(Nucleic Acid Amplification, (rPCR), ELISA,
(CLIA, Fluorescence assay), Rapid Test, NGS,
Western Blotting), Product (Instrument, Reagent
Kits, Software) End User (Blood Bank, Hospital)
- Global Forecasts to 2021"The global blood
screening market is expected to reach USD 2.80
Billion by 2021 from USD 1.76 Billion in 2016, at
a CAGR of 9.7 from 2016 to 2021 Browse 97
market data tables and 39 figures spread
through 150 pages and in-depth TOC on Blood
Screening Market   http//www.marketsandmarkets.c
om/Market-Reports/blood-screening-market-267747042
.html Early buyers will receive 10 customization
on this report.  The major factors driving the
growth of this market are increasing number of
blood donations and blood donors, growing
affordability and adoption of nucleic acid
amplification test (NAT) for blood screening,
rising awareness regarding the safety of donated
blood, growing demand for donated blood, and
increasing prevalence/incidence of infectious
diseases. http//www.marketsandmarkets.com/Market
-Reports/blood-screening-market-267747042.html .
3
Blood screening is a medical process in which
donated blood is mainly tested for HIV1, HIV2,
HBV, HCV, malaria, syphilis, and various other
infectious diseases. Donated blood is screened
for these infectious diseases to reduce the risk
of transfusion-transmitted infections
(TTIs). Download PDF Broacher http//www.markets
andmarkets.com/pdfdownload.asp?id267747042 This
report segments the blood screening market on the
basis of technology, product service, end user,
and region Based on technology, the market is
segmented into NAT, ELISA, rapid tests, western
blot assays, and NGS. The NAT segment is further
subsegmented into TMA and real-time PCR. The
ELISA technology segment is further categorized
into various generations and platforms. On the
basis of generation, the ELISA segment is further
divided into first generation ELISA, second
generation ELISA, third generation ELISA, and
fourth above generation ELISA. .
http//www.marketsandmarkets.com/Market-Reports/bl
ood-screening-market-267747042.html
4
On the basis of product and service, the blood
screening market is segmented into reagents
kits, instruments, and software services. The
reagents kits segment is further subsegmented
into NAT, ELISA, and other reagents and kits. The
instrument segment is categorized based on
purchase mode and is further subsegmented into
rental purchase and outright purchase. Download
Sample Pages of this Report_at_ http//www.marketsand
markets.com/requestsample.asp?id267747042 On
the basis of end user, the blood screening market
is segmented into blood banks and hospitals. The
blood banks segment is expected to account for
the largest share of the market in 2016. Major
factors driving the growth of this segment are
the increasing demand for donated blood, growing
number of organ transplantation surgeries, rising
awareness regarding the safety of blood,
increasing number of donations worldwide, and
growth in government funding to charitable
trusts.  
http//www.marketsandmarkets.com/Market-Reports/bl
ood-screening-market-267747042.html
5
On the basis of region, the blood screening
market is segmented into North America, Europe,
Asia, and the Rest of the World (RoW). North
America is expected to account for the largest
share of the market in 2016. Growth in this
regional segment is driven by factors such as
increasing adoption of nucleic acid tests (NAT)
and increasing participation of various
government associations in blood donations and
screening transfusion activities . Key players
in the blood screening market include Grifols
(Spain), Thermo Fisher Scientific, Inc. (U.S.),
Roche Diagnostics (Switzerland), bioMérieux
(France), Bio-Rad Laboratories, Inc. (U.S.),
Siemens Healthineers (Germany), Abbott
Laboratories (U.S.), Ortho Clinical Diagnostics,
Inc. (U.S.), Becton, Dickinson and Company
(U.S.), and Beckman Coulter, Inc. (U.S.).
http//www.marketsandmarkets.com/Market-Reports/bl
ood-screening-market-267747042.html
6
About MarketsandMarkets MarketsandMarkets
provides quantified B2B research on 30,000 high
growth niche opportunities/threats which will
impact 70 to 80 of worldwide companies
revenues. Currently servicing 5000 customers
worldwide including 80 of global Fortune 1000
companies as clients. Almost 75,000 top officers
across eight industries worldwide approach
MarketsandMarkets for their painpoints around
revenues decisions.   Our 850 fulltime analyst
and SMEs at MarketsandMarkets are tracking
global high growth markets following the "Growth
Engagement Model GEM". The GEM aims at
proactive collaboration with the clients to
identify new opportunities, identify most
important customers, write "Attack, avoid and
defend" strategies, identify sources of
incremental revenues for both the company and its
competitors. MarketsandMarkets now coming up
with 1,500 MicroQuadrants (Positioning top
players across leaders, emerging companies,
innovators, strategic players) annually in high
growth emerging segments. MarketsandMarkets is
determined to benefit more than 10,000 companies
this year for their revenue planning and help
them take their innovations/disruptions early to
the market by providing them research ahead of
the curve.   MarketsandMarketss flagship
competitive intelligence and market research
platform, "RT" connects over 200,000 markets and
entire value chains for deeper understanding of
the unmet insights along with market sizing and
forecasts of niche markets.   
httphttp//www.marketsandmarkets.com/Market-Report
s/blood-screening-market-267747042.html
7
Contact Us
Mr. Rohan MarketsandMarkets 701 Pike Street
Suite 2175, Seattle, WA 98101, United States
Tel [phone] Email sales_at_marketsandmarket
s.com MarketsandMarkets Bloghttp//www.marketsan
dmarkets.comhttp//twitter.com/marketsmarkets htt
p//www.linkedin.com/company/marketsandmarkets